Nebius Stock: A 571% Quarter Meets a $27 Billion Bill — and a 2027 Deadline That Does the Grading
Published on 11/18/2026 at 05:01 | Editorial boerse-global.deNebius just posted one of the fastest growth rates on record for a company its size. Revenue for the third quarter of 2026 came in at $980.8 million, up 571% year over year, according to the company's Thursday disclosure. Strip everything else away and that number alone would normally settle the argument.
It doesn't, because the same disclosure carried two items that pull in the opposite direction. Nebius now expects full-year revenue at the low end of its $3.0 billion to $3.4 billion range. And a chunk of the revenue it had counted on will not arrive until 2027, after capacity from third-party data centers slipped into the first half of next year.
That combination — explosive backward-looking growth, a trimmed forward outlook, and a schedule that has moved — is what investors are actually being asked to price. The debate is no longer growth versus valuation. It is whether revenue that has been pushed out will land at all.
The distinction that matters
A delay and a shortfall are not the same thing, and the gap between them is where the investment case lives. If the third-party capacity comes online and the deferred revenue follows, the weaker near-term guidance reads as a timing setback. If the slippage repeats, the credibility of the entire plan deserves a harder look.
Should investors sell immediately? Or is it worth buying Nebius?
Nebius has framed the issue as a shift in timing, not a loss. That is the company's characterization, and it is not a guarantee of later collection. The proof will have to come from reported revenue, not from a schedule.
Against that, the capital plan has only grown more ambitious. Nebius raised its 2026 capital expenditure forecast to roughly $27 billion, up from a prior range of $20 billion to $25 billion. For 2027, the company projects capex of $40 billion to $45 billion. The buildout, in other words, does not taper after the current year — it accelerates.
When spending outruns proof
Here is the tension in its purest form: the larger the outlay, the more the calendar matters. A bigger capex number says something about intended spending. It says nothing about return. The scenario that would hurt most is not deferred revenue on its own — it is higher spending colliding with repeated delays, which would raise expectations for future business while the operating evidence stays missing.
That framing fits the wider conversation about AI infrastructure. Reuters reported on November 11 that concerns over infrastructure spending had contributed to an earlier selloff in AI stocks. Nebius offers a concrete case study: strong growth, rising costs, and capacity that has moved.
The Street splits the difference
Analyst reaction has been varied rather than uniform, and the spread is instructive. Citi's Tyler Radke cut his price target to $215 from $265 while keeping a Buy rating, according to media reports. D.A. Davidson's Gil Luria went further, halving his target to $125 from $250 on Friday and holding at Neutral.
Nebius at a turning point? This analysis reveals what investors need to know now.
A lower target with an unchanged Buy is neither an all-clear nor a rejection of the growth story. A halved target at Neutral does not disprove the potential either — it measures how much confidence is being extended to revenue that has not yet shown up. What the two moves share is a refusal to treat the trailing quarter as sufficient evidence on its own.
What would settle it
The near-term checkpoint is straightforward: hitting the narrowed full-year revenue target. The bigger test is the handover of deferred revenue into 2027. Should the shift stay contained and the adjusted guidance be met, a constructive case can be built, and the discussion could rotate back toward growth. Should further delays pile up, the reliability of the plan will carry more weight than the historic growth rate.
Neither a single broker's target nor a 571% quarter answers that question. Only reported revenue from the deferred capacity will. Until then, the strong quarter earns attention — but the capex figure, on its own, earns no benefit of the doubt.
Ad
Nebius Stock: New Analysis - 18 November
Fresh Nebius information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
